ERBB2 and breast cancer: Targeted treatment has been developed for malignant diseases, such as non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutation [35, 36] and anaplastic lymphoma kinase (ALK) [37], and breast cancer with human epidermal growth factor receptor 2 [38, 39].